NewLink Genetics Corp. is evaluating what to do with its HyperAcute development program, which is active in a number of tumor types, following the failure of its algenpantucel-L vaccine in the Phase III IMPRESS study of resected pancreatic cancer.
NewLink’s HyperAcute Cellular Immunotherapies platform allows development of off-the-shelf active cancer vaccines made up of tumor cell lines engineered to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?